Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03882346
Other study ID # LC-BAL-18
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date March 29, 2019
Est. completion date June 2022

Study information

Verified date April 2020
Source HLB Cell Co., Ltd.
Contact Younyoung Hwang
Phone +82-2-2627-6773
Email yy.hwang@hlb-bio.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a prospective, comparative, open label, phase 2b study designed to investigate the safety and efficacy of LifeLiver (an Extracorporeal Bio Artificial Liver). The study will recruit approximately 40 acute or acute-on-chronic liver failure patients.


Description:

Patient should have acute or acute-on-chronic liver failure and be registered in KONOS (Korean Network for Organ Sharing) system as a candidate of liver transplantation. Patients who meet the eligibility criteria will be assigned to control group or experimental group. Experimental group patients will receive LifeLiver treatment in addition to the best supportive care for the disease.

Primary Objective:

1. To evaluate the efficacy of LifeLiver in terms of a comparison of 30 day-survival rate between control group and experimental group. (after patient's KONOS (Korean Network for Organ Sharing) registration date)

Secondary Objective:

1. To compare a median value of 2 week-survival rate and duration of survival between both study groups

2. Survival analysis respect to each group of patients divided according to the KONOS status

3. To investigate safety and change of overall efficacy indicators in terms of Glasgow Coma Scale, West Heaven Criteria for hepatic encephalopathy, MELD (Model for End-stage Liver Disease) score, blood ammonia, inflammatory cytokine


Recruitment information / eligibility

Status Recruiting
Enrollment 40
Est. completion date June 2022
Est. primary completion date March 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria:

- 18 to 60 years of age

- Acute or acute-on-chronic liver failure patients who is waiting for liver transplantation (KONOS liver transplant emergency grade 2 or 3)

- Hepatic encephalopathy grade II or above

- The following laboratory values must be documented within the screening period:

- INR (international normalized ratio) 2.0 or above

- Serum ammonia 56 micromole/L or above

- Total bilirubin 5mg/dL or above

- Body weight 45kg or above

- Patient who can not expect effective treatment or prolonged survival

- Patient or patient's legal representative willing to provide informed consent and commit to study procedures

Exclusion Criteria:

- Patient who has contraindication to plasmapheresis

- Severe hypotension (systolic blood pressure 80mmHg or less)

- Platelet < 15,000/mm3

- Contraindications to liver transplantation (sepsis, severe heart disease, uncontrollable hemorrhage, irreversible brain damage)

- Cerebral hemorrhage

- Positive HIV infection

- Serious or life-threatening hemorrhage just before initiation of the study

- Patients with high gastrointestinal bleeding tendency (a history or suspicion of gastrointestinal bleeding within last 3 months)

- Hepatocellular carcinoma patient with 7 (or more) tumors or a 6cm (or larger) diameter single tumor

- Pregnant or lactating women

- Antibiotics (beta-lactam family) hypersensitive and streptomycin, amphotericin B sensitive patients

- Patients with inappropriate condition to participate the study under investigator's judgement

Study Design


Intervention

Combination Product:
LifeLiver
LifeLiver is an extracorporeal bioartificial liver (BAL) system. The system has shown remarkable detoxification capacity and sustained hepatic functions and also provides a bridge to transplant for patients who are unable to receive timely liver transplantation.

Locations

Country Name City State
Korea, Republic of Samsung Medical Center Seoul

Sponsors (1)

Lead Sponsor Collaborator
HLB Cell Co., Ltd.

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary Survival rate for 30 days To compare survival rate of LifeLiver treatment with best supportive care up to 30 days
Primary Occurrence of clinical safety laboratory adverse events (AEs) To compare occurrence of clinical safety laboratory adverse events between Experimental group and Control group assessed according to NCI-CTCAE v5.0 up to approximately 12 months
Primary Incidence of transition of PERV (Porcine Endogenous Retrovirus) (for experimental group only) Number of reported PERV transition defined as viral detection in subject's blood by PCR (Polymerase Chain Reaction) test. up to approximately 12 months
Secondary Survival rate for 14 days To compare survival rate of LiveLiver treatment with best supportive care up to 14 days
Secondary Median value of duration of survival To compare Median value of duration of survival between experimental group and control group up to approximately 12 months
Secondary Kaplan-Meier estimate of subjects with MELD (Modell for End-stage Liver Disease) score >37 To compare Kaplan-Meier estimate of both (experimental and control) groups at 14 days and 30 days up to 30 days
Secondary Kaplan-Meier estimate of subjects with 31= MELD score =37 To compare Kaplan-Meier estimate of both groups at 14 days and 30 days up to 30 days
Secondary Comparison of MELD score Intra-group comparison (between pre and post 12 hours of LifeLiver treatment) and Inter-group comparison (between both groups) of subject's MELD score (range of minimum 6 to maximum 40) up to approximately 12hours after completion of LifeLiver treatment
Secondary Comparison of subject's neurological status - hepatic encephalopathy grade Intra-group comparison (between pre and post 12 hours of LifeLiver treatment) and Inter-group comparison (between both groups) of subject's hepatic encephalopathy grade (range of minimum 1 to maximum 4) up to approximately 12 hours after completion of LifeLiver treatment
Secondary Comparison of subject's neurological status - Glasgow Coma Scale Intra-group comparison (between pre and post 12 hours of LifeLiver treatment) and Inter-group comparison (between both groups) of subject's Glasgow Coma Scale (range of minimum 3 to maximum 15) up to approximately 12 hours after completion of LifeLiver treatment
Secondary Comparison of subject's value of blood ammonia Intra-group comparison (between pre and post 12 hours of LifeLiver treatment) and Inter-group comparison (between both groups) of subject's value of blood ammonia up to approximately 12 hours after completion of LifeLiver treatment
Secondary Comparison of subject's value of inflammatory cytokines Intra-group comparison (between pre and post 12 hours of LifeLiver treatment) and Inter-group comparison (between both groups) of subject's value of inflammatory cytokines (TNF-a, Interleukin-6, Interleukin-10) up to approximately 12 hours after completion of LifeLiver treatment
See also
  Status Clinical Trial Phase
Recruiting NCT05985863 - Human Umbilical Cord Mesenchymal Stem Cell Transplantation for The Treatment of Acute-on-Chronic Liver Failure Phase 1/Phase 2
Not yet recruiting NCT04822922 - Safety of UC-MSC Transfusion for ACLF Patients Phase 2
Recruiting NCT04578301 - Predicting Acute-on-Chronic Liver Failure After Surgical Intervention in Chronic Liver Disease
Completed NCT04983108 - Utility of Liver and Splenic Stiffness in Predicting Esophageal Varices in Patients With Acute on Chronic Liver Failure
Withdrawn NCT05940610 - The Safety and Efficacy of MSC-EVs in Acute/Acute-on-Chronic Liver Failure Phase 1/Phase 2
Not yet recruiting NCT05036031 - Transplantation for EASL-CLIF and APASL ACLF Patients: a Retrospective Cohort Study
Recruiting NCT05019352 - Cytokine Adsorption in Acute-on-chronic Liver Failure N/A
Recruiting NCT05421351 - Immune Profile, Neuronal Dysfunction, Metabolomics and Ammonia in Therapeutic Response of HE in ACLF
Completed NCT02321371 - Effect of Goal Directed Ammonia Lowering Therapy in Acute on Chronic Liver Failure Patients With Hepatic Encephalopathy. N/A
Not yet recruiting NCT06069037 - SALT for Treatment of Patients With Early ACLF N/A
Completed NCT02965560 - Exploring Biomarkers Predicting the Outcome of Acute-on-chronic Liver Failure
Recruiting NCT03713489 - Platelet Transfusion in HBV-related acute-on Chronic Liver Failure N/A
Withdrawn NCT03629015 - Safety Study of Stemchymal® in Acute Liver Failure Phase 1
Recruiting NCT04621812 - Role of Fecal Microbiota in Predicting Graft Rejection and Sepsis Among Recipients of Living Donor Liver Transplant in First Year.
Recruiting NCT04157465 - Anti-fungal Strategies in Acute-on-Chronic Liver Failure Patients N/A
Suspended NCT03737448 - TRimetazidine for acUte on Chronic Liver Failure STudy Phase 1
Recruiting NCT06128421 - Individual Nutrition Support in HBV-ACLF Patients at Nutrition Risk N/A
Recruiting NCT05700708 - Point-of-Care Echocardiography to Assess Impact of Dynamic Cardiac Function, Renal and Cardiac Biomarkers in Cirrhosis With Refractory Ascites
Completed NCT04238416 - Intravenous Branched Chain Amino Acids for Hepatic Encephalopathy in ACLF Phase 1
Completed NCT03456518 - Pattern of Acute on Chronic Liver Failure in Patient With HCV Related Chronic Liver Disease